The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells

(2010) Michaela Patz et al.   BRITISH JOURNAL OF HAEMATOLOGY

Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1

(2010) H. HATA et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma

(2009) Y. Terui et al.   CLINICAL CANCER RESEARCH

An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy

(2009) Y. Mishima et al.   CLINICAL CANCER RESEARCH

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure

(2009) N. A. Johnson et al.   HAEMATOLOGICA

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

(2009) A. W. Pawluczkowycz et al.   JOURNAL OF IMMUNOLOGY

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

(2008) A. Hagenbeek et al.   BLOOD

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2008) J. A. Engelman et al.   CLINICAL CANCER RESEARCH

CD20 Homo-oligomers Physically Associate with the B Cell Antigen Receptor

(2008) Maria J. Polyak et al.   JOURNAL OF BIOLOGICAL CHEMISTRY